Arbutus Biopharma (ABUS) Misses Q2 EPS by 1c

Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.23), $0.01 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $2.33 million versus the consensus estimate of $2.12 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
• PennyMac Mortgage Investment Trust (PMT) PT Lowered to $10 by UBS on Lower MSR Earnings
• ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04